Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 10OTHER 9NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 15Lymphoma, Large B-Cell, Diffuse 4Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 10fludarabine 7trametinib 6Specimen Handling 6Mycophenolic Acid 6Whole-Body Irradiation 5Sirolimus 5Nivolumab 5Biopsy 5fludarabine phosphate 4Magnetic Resonance Spectroscopy 4dabrafenib 3Prednisone 3Melphalan 3Ipilimumab 3GSK2636771 3Filgrastim 3Electrocardiography 3Crizotinib 3CTLA-4 Antigen 3Busulfan 3palbociclib 2osimertinib 2keyhole-limpet hemocyanin 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Mesna 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Neoplasms × venetoclax × Clear all
NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 20 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡